Renaissance Investment Group LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,931 shares of the company’s stock after buying an additional 201 shares during the quarter. Renaissance Investment Group LLC’s holdings in Johnson & Johnson were worth $2,320,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. First Trust Advisors LP grew its stake in shares of Johnson & Johnson by 61.4% during the first quarter. First Trust Advisors LP now owns 523,988 shares of the company’s stock valued at $73,248,000 after buying an additional 199,277 shares during the last quarter. Bath Savings Trust Co grew its stake in shares of Johnson & Johnson by 6.2% in the second quarter. Bath Savings Trust Co now owns 42,275 shares of the company’s stock worth $5,888,000 after purchasing an additional 2,479 shares during the last quarter. Cox Capital Mgt LLC grew its stake in shares of Johnson & Johnson by 0.6% in the second quarter. Cox Capital Mgt LLC now owns 19,920 shares of the company’s stock worth $2,774,000 after purchasing an additional 113 shares during the last quarter. Baystate Wealth Management LLC grew its stake in shares of Johnson & Johnson by 1.3% in the second quarter. Baystate Wealth Management LLC now owns 29,643 shares of the company’s stock worth $4,131,000 after purchasing an additional 372 shares during the last quarter. Finally, Deane Retirement Strategies Inc. grew its stake in shares of Johnson & Johnson by 0.7% in the second quarter. Deane Retirement Strategies Inc. now owns 12,379 shares of the company’s stock worth $1,724,000 after purchasing an additional 85 shares during the last quarter. Institutional investors own 72.25% of the company’s stock.
JNJ traded up $1.57 on Friday, hitting $133.00. The company had a trading volume of 4,856,974 shares, compared to its average volume of 7,224,392. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The stock has a fifty day simple moving average of $130.83 and a 200-day simple moving average of $134.05. The firm has a market capitalization of $343.25 billion, a P/E ratio of 16.26, a P/E/G ratio of 2.20 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The business had revenue of $20.73 billion during the quarter, compared to analyst estimates of $20.14 billion. During the same period last year, the business posted $2.05 earnings per share. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $0.95 dividend. The ex-dividend date is Monday, November 25th. This represents a $3.80 annualized dividend and a yield of 2.86%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
Several analysts recently issued reports on JNJ shares. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Friday, October 11th. Credit Suisse Group raised their target price on Johnson & Johnson from $158.00 to $163.00 in a research note on Thursday, October 24th. Atlantic Securities raised Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 target price on the stock in a research note on Thursday, October 17th. Finally, Wells Fargo & Co cut their target price on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $151.64.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What is the quiet period?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.